Search, Find and Buy Antibodies, ELISA Kits and Proteins.
Loading Loading
Order hotline:
phone +1 404 474 4654
fax +1 888 205 9894 (TF)
Details for Product No. ABIN969453

Vimentin (VIM) antibody

Request
Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Antigen
Synonyms CTRCT30, cb28, VIM, Vimentin, vim, vime
Reactivity
»Alternatives Human
Host
»Alternatives Mouse
Clonality (Clone) Monoclonal ()
Conjugate
»Alternatives Un-conjugated
Application
»Alternatives ELISA, Western Blotting (WB), Immunohistochemistry (IHC)
Pubmed 4 references available
Catalog no. ABIN969453
Quantity 100 µL
Price
363.00 $   Plus shipping costs $45.00
Shipping to
Availability Will be delivered in 3 to 4 Business Days
Immunogen Purified recombinant fragment of Vimentin expressed in E. coli.
Clone 9E7E7
Isotype IgG1
Purification Ascites
Alternative Name Vimentin
Background Synonyms:
FLJ36605, VIM
Vimentin is the major subunit protein of the intermediate filaments of mesenchymal cells. It is believed to be involved with the intracellular transport of proteins between the nucleus and plasma membrane. Vimentin has been implicated to be involved in the rate of steroid synthesis via its role as a storage network for steroidogenic cholesterol containing lipid droplets. Vimentin phosphorylation by a protein kinase causes the breakDaown of intermediate filaments and activation of an ATP and myosin light chain dependent contractile event. This results in cytoskelηl changes that facilitate the interaction of the lipid droplets within mitochondria, and subsequent transport of cholesterol to the organelles leading to an increase in steroid synthesis. Immunohistochemical staining for Vimentin is characteristic of sarcomas (of neural, muscle and fibroblast origin) compared to carcinomas which are generally negative. Melanomas, lymphomas and vascular tumors may all stain for Vimentin. Vimentin antibodies are thus of value in the differential diagnosis of undifferentiated neoplasms and malignant tumors. They are generally used with a panel of other antibodies including those recognising cytokeratins, lymphoid markers, S100, desmin and neurofilaments.
Gene ID 7431
Research Area Lineage Markers, Cytoskeleton, Neural Stem Cell marker, Cell/Tissue Markers
Application Notes Recommended Dilution:
ELISA: 1/10000, WB: 1/500 - 1/2000, IHC: 1/200 - 1/1000
Not yet tested in other applications.
Determining optimal working dilutions by titration test.
Restrictions For Research Use only
Format Liquid
Buffer Ascitic fluid containing 0.03 % sodium azide.
Preservative Sodium azide
Storage 4 °C/-20 °C
Storage Comment Store at 4 °C or at -20 °C for long term.
Product cited in: Chu, Seftor, Romer et al.: "Experimental coexpression of vimentin and keratin intermediate filaments in human melanoma cells augments motility." in: The American journal of pathology, Vol. 148, Issue 1, pp. 63-9, 1996 (PubMed).

Seshadri, Raymond, Leong et al.: "Vimentin expression is not associated with poor prognosis in breast cancer." in: International journal of cancer. Journal international du cancer, Vol. 67, Issue 3, pp. 353-6, 1996 (PubMed).

Essa, el Tatawi, Hamdi et al.: "Vimentin expression in different types of breast carcinoma immunohistochemical study." in: Journal of the Egyptian Society of Parasitology, Vol. 26, Issue 2, pp. 433-42, 1996 (PubMed).

Vanzi: "Freedom at home: state constitutions and Medicaid funding for abortions." in: New Mexico law review, Vol. 26, Issue 3, pp. 433-54, 2005 (PubMed).

Alternatives for antigen "Vimentin (VIM)", type "Antibodies"
Hosts (203), (169), (20), (6), (4), (4), (4)
Reactivities (353), (132), (120), (67), (63), (40), (38), (14), (13), (12), (9), (9), (5), (4), (4), (2), (2), (1), (1), (1), (1), (1), (1)
Applications (292), (140), (124), (95), (84), (72), (39), (36), (32), (30), (15), (6), (3), (3), (3), (2), (2), (2), (1), (1)
Conjugates (16), (14), (6), (5), (4), (3), (3), (3), (3), (3), (3), (3), (3), (3), (2), (2), (2)
Epitopes (19), (16), (16), (14), (8), (8), (5), (4), (4), (4), (3), (3), (3), (3), (2), (2), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
Beacon